Skip to content
Catalyst

PapersPMID:36307493

Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial.

Scientific reports2022The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidencelowersSerum creatinine concentration
  2. Finding, limited evidencelowersTotal leukocyte count
Study, every finding
RCT · 6 months
Dose studied, every finding
550 mg x 4 tablets per time, twice a day, 24 weeks, oral
  • “The changes in creatinine (Cre) at the 12th week (−0.1 ± 0.3) and 24th week (−0.2 ± 0.4) during oligo-fucoidan supplementation decreased more significantly than those in the control group at the 12th week (0.03 ± 0.07) and 24th week (0.07 ± 0.06) (p = 0.012 and p = 0.008).”
    Interests
    Industry funded
    Population
    Twenty adults with allergic asthma; both arms received regular asthma treatment; change from baseline at 12 and 24 weeks
  • “The change in WBC at 24th week (−1482.2 ± 1285.7) during supplementation with oligo-fucoidan decreased significantly more than that in the control group at 24th week (−589.0 ± 2835.0) (p = 0.038).”
    Interests
    Industry funded
    Population
    Twenty adults with allergic asthma; both arms received regular asthma treatment; change from baseline at 24 weeks

Study record

Design
randomised controlled trial
Species
human
Population
Outpatients with allergic asthma (Kuang-Tien General Hospital) on regular asthma treatment, given oligo-fucoidan or placebo
Participants
20
Comparator
placebo
Duration
168 days
Endpoints measured
97